DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0037583 A1 Pan Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0037583 A1 Pan Et Al US 20140O37583A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0037583 A1 Pan et al. (43) Pub. Date: Feb. 6, 2014 (54) METHODS AND COMPOSITIONS SUITABLE Publication Classification FOR PREVENTING AND TREATING HYPERLEPTNEMA (51) Int. Cl. A613 L/353 (2006.01) (76) Inventors: Yuanlong Pan, Chesterfield, MO (US); A2.3L I/30 (2006.01) Rondo Paul Middleton, Creve Coeur, A6II 45/06 (2006.01) MO (US) (52) U.S. Cl. CPC ............... A61 K3I/353 (2013.01); A61K 45/06 (21) Appl. No.: 14/112,050 (2013.01); A23L 1/3002 (2013.01) USPC ........................... 424/93.1: 514/456; 549/406 (22) PCT Filed: Apr. 17, 2012 (57) ABSTRACT (86) PCT NO.: PCT/US 12/33873 The invention provides methods and compositions Suitable for preventing and treating hyperleptinemia, preventing and S371 (c)(1), treating insulin resistance, preventing and treating cardiovas (2), (4) Date: Oct. 16, 2013 cular disease, preventing and treating obesity, preventing and treating hyperlipidemia, and preventing and treating hyper Related U.S. Application Data tension in an animal. The methods comprise administering (60) Provisional application No. 61/517,464, filed on Apr. one or more isoflavones to the animal, preferably in amounts 20, 2011. of from about 0.001 to about 10 g/kg/day. US 2014/0037583 A1 Feb. 6, 2014 METHODS AND COMPOSITIONS SUITABLE the isoflavones are administered to the animals in amount FOR PREVENTING AND TREATING from about 0.001 to about 10 grams per kilogram of body HYPERLEPTNEMA weight per day. 0011. Other and further objects, features, and advantages CROSS REFERENCE TO RELATED of the present invention will be readily apparent to those APPLICATIONS skilled in the art. 0001. This application claims priority to U.S. Provisional Application Ser. No. 61/517,464 filed Apr. 20, 2011, the DETAILED DESCRIPTION OF THE INVENTION disclosure of which is incorporated herein by this reference. Definitions BACKGROUND OF THE INVENTION 0012. The term “isoflavones' means isoflavones and their natural or synthetic analogs, derivatives, precursors, and 0002 1. Field of the Invention metabolites useful in the invention. Isoflavones refers to 0003. The invention relates generally to methods and com 3-phenylchromones, isomeric forms of flavones in which the positions useful for preventing and treating hyperleptinemia benzenegroup is attached to the 3 position of the benzopyran and particularly to the use of isoflavones for preventing and ring instead of the 2 position. Isoflavones may be found in a treating hyperleptinemia. number of Sources, including, but not limited to, Soy. Non 0004 2. Description of Related Art limiting examples of isoflavones include daidzein; daidzin, 0005 Isoflavones are naturally occurring chemical com 6-O-malonyl daidzein; 6-O-acetyl daidzein; genistein; 6-O- pounds found in plants such as beans and legumes, particu malonyl genistein; 6-O-acetyl genistein, glycitein; 6-O-ma larly Soy. Isoflavones mimic the effects of estrogen and modu lonyl glycitein; 6-O-acetyl. glycitein; Biochanin A; for late estrogen metabolism. As a result, isoflavones are known mononetin: irilone; prunetin: pratensein, glycitin; to reduce tumor cell proliferation, induce tumor cell apopto dihydrodaidzein, equol; O-desmethylangolensin; daidzein sis, regulate hormone balance, and reduce the risks of breast 7,4'-di-O-sulfate; daidzein 7-O-beta-D-glucuronide; daid and prostate cancer, heart disease, osteoporosis, and several Zein 4'-O-sulfate: 6,7,5'-trihydroxyisoflavone; 6.7.3',4'-tet other diseases and conditions. rahydroxyisoflavone; 7.8,4'-trihydroxyisoflavone; 5,6,7,4'- 0006. The metabolic hormone leptin plays a central role in tetrahydroxyisoflavone; dihydrogenistein; p-ethylphenol; food uptake and energy metabolism. It reduces appetite, 3',4'.5, 7-tetrahydroxyisoflavone; genistein 4'-O-sulfate: enhances energy expenditure, facilitates glucose utilization genistein 7-O-beta-D-glucuronide; genistein 4'-O-sulfate: and improves insulin sensitivity. However, high concentra and 4,5,7-trihydroxyisoflavanone. tions of leptin, a condition called hyperleptinemia, can result 0013 The term “animal' means any animal that can ben in leptin desensitization. Obese and overweight animals have efit from the regulation of leptin, e.g., a human, avian, bovine, high concentrations of leptin stored in adipose tissue and that canine, equine, feline, hicrine, lupine, murine, ovine, and can lead them to become resistant to the beneficial effects of porcine animals. leptin. Hyperleptinemia has many detrimental health effects, 0014. The term “companion animal' means domesticated including insulin resistance, cardiovascular disease, hyperph animals such as cats, dogs, rabbits, guinea pigs, ferrets, ham agia, hyperlipidemia, and hypertension. Sters, mice, gerbils, horses, cows, goats, sheep, donkeys, pigs, 0007. There is, therefore, a need for compositions and and the like. methods Suitable for preventing and treating hyperleptinemia 0015 The term “therapeutically-effective amount’ means in an animal. There is also a need for compositions and an amount of a compound of the present invention that (i) methods for preventing and treating insulin resistance, pre treats or prevents the particular disease, condition, or disor venting and treating cardiovascular disease, and preventing der, (ii) attenuates, ameliorates, or eliminates one or more and treating obesity, preventing and treating hyperlipidemia, symptoms of the particular disease, condition, or disorder, or and preventing and treating hypertension. Such therapies (iii) prevents or delays the onset of one or more symptoms of would be particularly useful in overweight, obese and aging the particular disease, condition, or disorder described herein. humans and other animals to improve the overall quality of 0016. The term “hyperleptinemia-related conditions' life for all involved. For companion animals, these therapies means any disease or condition that results from elevated would lead to improved owner satisfaction and would concentrations of leptin. Examples of hyperleptinemia-re improve the owner-companion animal bond. lated conditions include, but are not limited to, hyperphagia, insulin resistance, cardiovascular disease, metabolic Syn SUMMARY OF THE INVENTION drome, hyperlipidemia, atherosclerosis, myocardial infarc 0008. It is, therefore, an object of the invention to provide tion, stroke, and hypertension. methods and compositions Suitable for preventing and treat (0017. The terms “treating, “treat”, and “treatment” ing hyperleptinemia in an animal. embrace both preventative, i.e., prophylactic, and palliative 0009. It is another object of the invention to provide meth treatment. ods and compositions suitable for preventing and treating 0018. The terms “pharmaceutically acceptable' and insulin resistance, preventing and treating cardiovascular dis “nutraceutically acceptable' indicates that the substance or ease, preventing and treating obesity, preventing and treating composition must be compatible chemically and/or toxico hyperlipidemia, and preventing and treating hypertension in logically, with the other ingredients comprising a formula an animal. tion, and/or the mammal being treated therewith. 0010. One or more of these or other objects are achieved 0019. The term “health and/or wellness of an animal' by administering to an animal one or more isoflavones in a means the complete physical, mental, and Social well being of therapeutically effective amount. In general embodiments, the animal, not merely the absence of disease or infirmity. US 2014/0037583 A1 Feb. 6, 2014 0020. The term “extending the prime” means extending 0028. The dosages expressed herein are in milligrams per the number of years an animal lives a healthy life and not just kilogram of body weight per day (mg/kg/day) unless extending the number of years an animal lives, e.g., an animal expressed otherwise. would be healthy in the prime of its life for a relatively longer 0029 All percentages expressed herein are by weight of time. the composition on a dry matter basis unless specifically 0021. The term “in conjunction' means that compositions stated otherwise. The skilled artisan will appreciate that the of the invention are administered to an animal (1) together in term “dry matter basis' means that an ingredient's concen a food composition or (2) separately at the same or different tration or percentage in a composition is measured or deter frequency using the same or different administration routes at mined after any free moisture in the composition has been about the same time or periodically. “Periodically’ means removed. that compositions are administered on a schedule acceptable 0030. As used herein, ranges are used herein in shorthand, for specific compounds or compositions. About the same So as to avoid having to list and describe each and every value time' generally means that compositions are administered at within the range. Any appropriate value within the range can the same time or within about 72 hours of each other. be selected, where appropriate, as the upper value, lower value, or the terminus of the range. 0022. The term “dietary supplement’ means a product that 0031. As used herein, the singular form of a word includes is intended to be ingested in addition to a normal animal diet. the plural, and vice versa, unless the context clearly dictates Dietary Supplements may be in any form, e.g., Solid, liquid, otherwise. Thus, the references “a”, “an', and “the are gen gel, tablet, capsule, powder, and the like.
Load more

Recommended publications
  • The Proceedings of the Conference on the Challenges of Contemporary Cell Biology Molecular Genetics, System Biology, Bioinformatics
    University of Lodz The Proceedings of the Conference on The Challenges of Contemporary Cell Biology Molecular Genetics, System Biology, Bioinformatics April 20 – 21, 2009 The Conference to Honor Professor Maria J. Olszewska on Her Jubilee Łódź University Press, 2009 Conference on The Challenges of Contemporary Cell Biology – April 20-21, 2009 Sponsors of the Conference 2 Conference on The Challenges of Contemporary Cell Biology – April 20-21, 2009 Patronage: Rector of the University of Lodz – Professor Włodzimierz Nykiel, Ph.D. Conference supported by Polish Ministry of Science and Higher Education Conference Organizers: The Committee on Cell Biology of Polish Academy of Sciences Institute of Physiology, Cytology, and Cytogenetics, University of Lodz The Lodz Branch of the Polish Academy of Sciences Organizing Committee: Chairman: Andrzej K. Kononowicz – University of Lodz Vice-Chairman: Elżbieta Wyroba – The Committee on Cell Biology of Polish Academy of Sciences Members: Maria Kwiatkowska – University of Lodz Jerzy Kawiak – Editor of Advances in Cell Biology (Postępy Biologii Komórki) Barbara Gabara – University of Lodz Mirosław Godlewski – University of Lodz Jacek Jurczakowski – The Lodz Branch of the Polish Academy of Sciences Kazimierz Marciniak – University of Lodz Janusz Maszewski – University of Lodz Maria Skłodowska – University of Lodz Scientific Committee: Maria Kwiatkowska – University of Lodz Jerzy Kawiak – Editor of Advances in Cell Biology (Postępy Biologii Komórki) Andrzej K. Kononowicz – University of Lodz Janusz Maszewski – University of Lodz Conference Office: Ewa Mikołajczyk-Zając – University of Lodz Violetta Macioszek – University of Lodz Katarzyna Hnatuszko-Konka – University of Lodz (Book cover and Conference website design) Tomasz Kowalczyk – University of Lodz Department of Genetics and Plant Molecular Biology and Biotechnology Faculty of Biology and Environmental Protection University of Lodz S.
    [Show full text]
  • Phytochem Referenzsubstanzen
    High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.286. ABIETIC ACID Sylvic acid [514-10-3] 302.46 C20H30O2 01.030. L-ABRINE N-a-Methyl-L-tryptophan [526-31-8] 218.26 C12H14N2O2 Merck Index 11,5 01.031. (+)-ABSCISIC ACID [21293-29-8] 264.33 C15H20O4 Merck Index 11,6 01.032. (+/-)-ABSCISIC ACID ABA; Dormin [14375-45-2] 264.33 C15H20O4 Merck Index 11,6 01.002. ABSINTHIN Absinthiin, Absynthin [1362-42-1] 496,64 C30H40O6 Merck Index 12,8 01.033. ACACETIN 5,7-Dihydroxy-4'-methoxyflavone; Linarigenin [480-44-4] 284.28 C16H12O5 Merck Index 11,9 01.287. ACACETIN Apigenin-4´methylester [480-44-4] 284.28 C16H12O5 01.034. ACACETIN-7-NEOHESPERIDOSIDE Fortunellin [20633-93-6] 610.60 C28H32O14 01.035. ACACETIN-7-RUTINOSIDE Linarin [480-36-4] 592.57 C28H32O14 Merck Index 11,5376 01.036. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- a-D-Glucosamine pentaacetate 389.37 C16H23NO10 ACETYL-a-D-GLUCOPYRANOSE 01.037. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- b-D-Glucosamine pentaacetate [7772-79-4] 389.37 C16H23NO10 ACETYL-b-D-GLUCOPYRANOSE> 01.038. 2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL- Acetochloro-a-D-glucosamine [3068-34-6] 365.77 C14H20ClNO8 a-D-GLUCOPYRANOSYLCHLORIDE - 1 - High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.039.
    [Show full text]
  • Ep 3138585 A1
    (19) TZZ¥_¥_T (11) EP 3 138 585 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.03.2017 Bulletin 2017/10 A61L 27/20 (2006.01) A61L 27/54 (2006.01) A61L 27/52 (2006.01) (21) Application number: 16191450.2 (22) Date of filing: 13.01.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Gousse, Cecile GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74230 Dingy Saint Clair (FR) PL PT RO RS SE SI SK SM TR • Lebreton, Pierre Designated Extension States: 74000 Annecy (FR) BA ME •Prost,Nicloas 69440 Mornant (FR) (30) Priority: 13.01.2010 US 687048 26.02.2010 US 714377 (74) Representative: Hoffmann Eitle 30.11.2010 US 956542 Patent- und Rechtsanwälte PartmbB Arabellastraße 30 (62) Document number(s) of the earlier application(s) in 81925 München (DE) accordance with Art. 76 EPC: 15178823.9 / 2 959 923 Remarks: 11709184.3 / 2 523 701 This application was filed on 29-09-2016 as a divisional application to the application mentioned (71) Applicant: Allergan Industrie, SAS under INID code 62. 74370 Pringy (FR) (54) STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES (57) The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. EP 3 138 585 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 138 585 A1 Description CROSS REFERENCE 5 [0001] This patent application is a continuation-in-part of U.S.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis Chemical Activity Count (+)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (+)-8HYDROXYCALAMENENE 1 (+)-ALLOMATRINE 1 (+)-ALPHA-VINIFERIN 3 (+)-AROMOLINE 1 (+)-CASSYTHICINE 1 (+)-CATECHIN 10 (+)-CATECHIN-7-O-GALLATE 1 (+)-CATECHOL 1 (+)-CEPHARANTHINE 1 (+)-CYANIDANOL-3 1 (+)-EPIPINORESINOL 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALBACIN 2 (+)-GALLOCATECHIN 3 (+)-HERNANDEZINE 1 (+)-ISOCORYDINE 2 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 2 (+)-T-CADINOL 1 (+)-VESTITONE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (-)-ACANTHOCARPAN 1 (-)-ALPHA-BISABOLOL 2 (-)-ALPHA-HYDRASTINE 1 Chemical Activity Count (-)-APIOCARPIN 1 (-)-ARGEMONINE 1 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANESCACARPIN 1 (-)-CENTROLOBINE 1 (-)-CLANDESTACARPIN 1 (-)-CRISTACARPIN 1 (-)-DEMETHYLMEDICARPIN 1 (-)-DICENTRINE 1 (-)-DOLICHIN-A 1 (-)-DOLICHIN-B 1 (-)-EPIAFZELECHIN 2 (-)-EPICATECHIN 6 (-)-EPICATECHIN-3-O-GALLATE 2 (-)-EPICATECHIN-GALLATE 1 (-)-EPIGALLOCATECHIN 4 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 9 (-)-EUDESMIN 1 (-)-GLYCEOCARPIN 1 (-)-GLYCEOFURAN 1 (-)-GLYCEOLLIN-I 1 (-)-GLYCEOLLIN-II 1 2 Chemical Activity Count (-)-GLYCEOLLIN-III 1 (-)-GLYCEOLLIN-IV 1 (-)-GLYCINOL 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-ISOSATIVAN 1 (-)-JASMONIC-ACID 1 (-)-KAUR-16-EN-19-OIC-ACID 1 (-)-MEDICARPIN 1 (-)-VESTITOL 1 (-)-VESTITONE 1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse Et Al
    US 20120208890A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse et al. (43) Pub. Date: Aug. 16, 2012 (54) STABLE HYDROGEL COMPOSITIONS of application No. 127956,542, filed on Nov.30, 2010, INCLUDING ADDITIVES which is a continuation-in-part of application No. 12/714,377, filed on Feb.26, 2010, which is a continu (75) Inventors: Cecile Gousse, Dingy Saint Clair ation-in-part of application No. 12/687,048, filed on (FR); Pierre F. Lebreton, Annecy Jan. 13, 2010. (FR); Nicolas Prost, Mornant (FR): Sumit Paliwal, Goleta, CA (US); Publication Classification Dennis Van Epps, Goleta, CA (US) (51) Int. C. (73) Assignee: ALLERGAN, INC. Irvine, CA A6IR 8/4I (2006.01) (US) A61O 19/08 (2006.01) A6IR 8/42 (2006.01) (21) Appl. No.: 13/350,518 (52) U.S. Cl. ......................................... 514/626; 514/653 (22) Filed: Jan. 13, 2012 (57) ABSTRACT Related U.S. Application Data The present specification generally relates to hydrogel com (63) Continuation-in-part of application No. 13/005,860, positions and methods of treating a soft tissue condition using filed on Jan. 13, 2011, which is a continuation-in-part Such hydrogel compositions. Patent Application Publication Aug. 16, 2012 Sheet 1 of 7 US 2012/0208890 A1 lication Publication ug. 16, 2012 Sheet 2 of 7 co & S. N SESo 9 CD s Y NI C O O CN ve ve D an an 5 S. 5 3. 9. S. Patent Application Publication Aug. 16, 2012 Sheet 3 of 7 US 2012/0208890 A1 00Z?000).00800900700Z0 O.GZ?eSÅep~ Patent Application Publication Aug.
    [Show full text]
  • Prenylated Isoflavonoids from Soya and Licorice
    Prenylated isoflavonoids from soya and licorice Analysis, induction and in vitro estrogenicity Rudy Simons Thesis committee Thesis supervisor: Prof. Dr. Ir. Harry Gruppen Professor of Food Chemistry Wageningen University Thesis co-supervisor : Dr. Ir. Jean-Paul Vincken Assistent Professor, Laboratory of Food Chemistry Wageningen University Other members : Prof. Dr. Renger Witkamp Wageningen University Dr. Nigel Veitch Royal Botanic Gardens, Kew, United Kingdom Prof. Dr. Robert Verpoorte Leiden University Dr. Henk Hilhorst Wageningen University This research was conducted under the auspices of the Graduate School VLAG ( Voeding, Levensmiddelentechnologie, Agrobiotechnologie en Gezondheid ) Prenylated isoflavonoids from soya and licorice Analysis, induction and in vitro estrogenicity Rudy Simons Thesis submitted in fulfilment of the requirements of the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr. M.J. Kropff in the presence of the Thesis Committee appointed by the Academic Board To be defended in public on Tuesday 28 June 2011 at 1.30 p.m. in the Aula. Rudy Simons Prenylated isoflavonoids from soya and licorice Analysis, induction and in vitro estrogenicity Ph.D. thesis, Wageningen University, Wageningen, the Netherlands (2011) With references, with summaries in Dutch and English ISBN: 978-90-8585-943-7 ABSTRACT Prenylated isoflavonoids are found in large amounts in soya bean ( Glycine max ) germinated under stress and in licorice ( Glycyrrhiza glabra ). Prenylation of isoflavonoids has been associated with modification of their estrogenic activity. The aims of this thesis were (1) to provide a structural characterisation of isoflavonoids, in particular the prenylated isoflavonoids occurring in soya and licorice, (2) to increase the estrogenic activity of soya beans by a malting treatment in the presence of a food-grade fungus, and (3) to correlate the in vitro agonistic/antagonistic estrogenicity with the presence of prenylated isoflavonoids.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis Chemical Activity Count (+)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (+)-8HYDROXYCALAMENENE 1 (+)-ALLOMATRINE 1 (+)-ALPHA-VINIFERIN 3 (+)-AROMOLINE 1 (+)-CASSYTHICINE 1 (+)-CATECHIN 10 (+)-CATECHIN-7-O-GALLATE 1 (+)-CATECHOL 1 (+)-CEPHARANTHINE 1 (+)-CYANIDANOL-3 1 (+)-EPIPINORESINOL 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALBACIN 2 (+)-GALLOCATECHIN 3 (+)-HERNANDEZINE 1 (+)-ISOCORYDINE 2 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 2 (+)-T-CADINOL 1 (+)-VESTITONE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (-)-ACANTHOCARPAN 1 (-)-ALPHA-BISABOLOL 2 (-)-ALPHA-HYDRASTINE 1 Chemical Activity Count (-)-APIOCARPIN 1 (-)-ARGEMONINE 1 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANESCACARPIN 1 (-)-CENTROLOBINE 1 (-)-CLANDESTACARPIN 1 (-)-CRISTACARPIN 1 (-)-DEMETHYLMEDICARPIN 1 (-)-DICENTRINE 1 (-)-DOLICHIN-A 1 (-)-DOLICHIN-B 1 (-)-EPIAFZELECHIN 2 (-)-EPICATECHIN 6 (-)-EPICATECHIN-3-O-GALLATE 2 (-)-EPICATECHIN-GALLATE 1 (-)-EPIGALLOCATECHIN 4 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 9 (-)-EUDESMIN 1 (-)-GLYCEOCARPIN 1 (-)-GLYCEOFURAN 1 (-)-GLYCEOLLIN-I 1 (-)-GLYCEOLLIN-II 1 2 Chemical Activity Count (-)-GLYCEOLLIN-III 1 (-)-GLYCEOLLIN-IV 1 (-)-GLYCINOL 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-ISOSATIVAN 1 (-)-JASMONIC-ACID 1 (-)-KAUR-16-EN-19-OIC-ACID 1 (-)-MEDICARPIN 1 (-)-VESTITOL 1 (-)-VESTITONE 1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0224164 A1 Lebreton (43) Pub
    US 20110224164A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0224164 A1 Lebreton (43) Pub. Date: Sep. 15, 2011 (54) FLUID COMPOSITIONS FOR IMPROVING Publication Classification SKIN CONDITIONS (51) Int. Cl. (75) Inventor: Pierre F. Lebreton, Annecy (FR) 3G 0.O :08: (73) Assignee: Allergan Industrie, SAS, Pringy (FR) (52) U.S. Cl. .......................................................... 514/54 (21)21) Appl. NoNo.: 12/777,1069 (57) ABSTRACT (22) Filed: May 10, 2010 The present specification discloses fluid compositions com O O prising a matrix polymerand stabilizing component, methods Related U.S. Application Data of making Such fluid compositions, and methods of treating (60) Provisional application No. 61/313,664, filed on Mar. skin conditions in an individual using Such fluid composi 12, 2010. tions. Patent Application Publication Sep. 15, 2011 Sheet 1 of 3 US 2011/0224164 A1 girl is" . .... i E.- &;',EE 3 isre. fire;Sigis's Patent Application Publication Sep. 15, 2011 Sheet 2 of 3 US 2011/0224164 A1 Wiscosity"in a a set g : i?vs. iii.tige: ssp. r. E. site is Patent Application Publication Sep. 15, 2011 Sheet 3 of 3 US 2011/0224164 A1 Fi; ; ; ; , ; i 3 -i-...-- m M mommam mm M. M. MS ' ' s 6. ;:S - - - is : s s: s e 3. 83 8 is is a is É . ; i: ; ------es----- .- mm M. Ma Yum YM Mm - m - -W Mmm-m a 'm m - - - S. 'm - i. So m m 3 - - - - - - - - --- f ; : : ---- ' - - - - - - - - - - - - - - - . : 2. ----------- US 2011/0224164 A1 Sep. 15, 2011 FLUID COMPOSITIONS FOR IMPROVING 0004. The fluid compositions disclosed in the present SKIN CONDITIONS specification achieve this goal.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Pesticide
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Pesticide Chemical Dosage (+)-(1S,10R)-1,10-DIMETHYLBICYCLO(4.4.
    [Show full text]
  • Phytochemical Analysis of Isoflavonoids Using Liquid
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/275018881 Phytochemical analysis of isoflavonoids using liquid chromatography coupled with tandem mass spectrometry Article in Phytochemistry Reviews · March 2015 CITATIONS READS 0 587 4 authors, including: Kanumuri Siva Rama Raju Isha Taneja University of Florida Central Drug Research Institute 72 PUBLICATIONS 835 CITATIONS 50 PUBLICATIONS 576 CITATIONS SEE PROFILE SEE PROFILE Muhammad Wahajuddin Central Drug Research Institute 130 PUBLICATIONS 2,243 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Targeting GPCRs for the development novel therapeutics for obesity View project Identification & evaluation of candidate drug target from natural plant resources, chemical synthetic routes, chemical modification for their anti - diabetic. View project All content following this page was uploaded by Kanumuri Siva Rama Raju on 17 April 2015. The user has requested enhancement of the downloaded file. Phytochem Rev DOI 10.1007/s11101-015-9400-x Phytochemical analysis of isoflavonoids using liquid chromatography coupled with tandem mass spectrometry Kanumuri Siva Rama Raju • Naveen Kadian • Isha Taneja • M. Wahajuddin Received: 31 December 2014 / Accepted: 12 March 2015 Ó Springer Science+Business Media Dordrecht 2015 Abstract Isoflavonoids are the biologically active made it possible to analyse and characterize several secondary metabolites of plants that are being used for constituents and their metabolites in a single run along several health promoting and restoring effects medi- with high selectivity and sensitivity. In this review, we ated through different pathways. Isoflavonoids are have summarised the application of LC–MS/MS for structurally similar to estrogens due to which also the identification and quantification of isoflavonoids known as phytoestrogens and have shown potent reported for various plant extracts and food products estrogenic and anti-estrogenic activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0020950 A1 Lambers Et Al
    US 20170020950A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0020950 A1 Lambers et al. (43) Pub. Date: Jan. 26, 2017 (54) METHODS FOR MODULATING KINASES (52) U.S. Cl. CPC ............. A61K 38/018 (2013.01); A61K 35/74 (71) Applicant: Mead Johnson Nutrition Company, (2013.01); A61K 35/741 (2013.01); A61 K Glenview, IL (US) 3 1/716 (2013.01); A23L I/296 (2013.01); A2.3L I/3056 (2013.01); A23 V 2002/00 (72) Inventors: Teartse Tim Lambers, Nijmegen (NL); (2013.01) Eric A.F. van Tol, Arnhem (NL); Sarmauli Manurung, Nijmegen (NL) (57) ABSTRACT (21) Appl. No.: 14/806,877 A method for modulating a kinase by administering to a (22) Filed: Jul. 23, 2015 Subject a nutritional composition comprising extensively hydrolyzed casein, extensively hydrolyzed casein fractions, Publication Classification or combinations thereof. A modulated kinase may be a (51) Int. Cl. kinase that regulates inflammatory signaling, immune tol A6 IK 38/0 (2006.01) erance, metabolic signaling, cell cycle and growth factor A6 IK 35/74 (2006.01) signaling. The nutritional composition may dose-depend A6 IK3I/76 (2006.01) ently inhibit a range of serine, threonine and tyrosine A6 IK 35/74 (2006.01) kinases. US 2017/0020950 A1 Jan. 26, 2017 METHODS FOR MODULATING KNASES 0010. The nutritional composition in the disclosed method may be an infant formula, and may, in Some embodi TECHNICAL FIELD ments, further comprise fat, carbohydrate, probiotic, prebi 0001. This disclosure relates to methods of modulating otic, or combinations thereof. The prebiotic may include specific kinase activity by administering extensively hydro polydextrose and/or galacto-oligosaccharide.
    [Show full text]
  • Fungal Transformation of the Antifungal Isoflavone Luteone Satoshi Tahara, Shiro Nakahara, Junya Mizutani and John L
    Agric. Biol. Chem., 48 (6), 1471 ~ 1477, 1984 1471 Fungal Transformation of the Antifungal Isoflavone Luteone Satoshi Tahara, Shiro Nakahara, Junya Mizutani and John L. Ingham* Department of Agricultural Chemistry, Faculty of Agriculture, Hokkaido University, Kita-ku, Sapporo 060, Japan *Phytochemical Unit, Department of Botany, University of Reading, Whiteknights, Reading RG6 2AS, England Received November 4, 1983 An antifungal isoflavone, luteone [5,7,2/,4/-tetrahydroxy-6-(3,3-diniethylallyl)isoflavone] is metabolised by cultures of Aspergillus flavus and Botrytis cinerea into 2",3"-dihydro-3"- hydroxyluteone (AF- 1), 2//,3 '/-dihydrodihydroxyluteone, a dihydrofuranoisoflavone (BG-1) and a dihydropyranoisoflavone. The structures of the metabolites were elucidated by physico-chemical and chemical procedures. The major metabolites, AF-1 and BC-1 are much less toxic than luteone against Cladosporium herbarum. The possible metabolic pathways are briefly discussed. SJ^^'-Tetrahydroxy^-^B-dimethyl- demethylating or reducing the molecule.6'7* allyl)isoflavone (luteone, 1) was first isolated In the case of 5,7,2',4'-tetrahydroxy-8-(3,3- from the young fruits of Lupinus luteus L. dimethylallyl)isoflavanone (kievitone) and 3,9- (yellow lupin) and found to be strongly dihydroxy- 1 0-(3, 3-dimethylallyl)pterocarpan antifungal.1) Considerable quantities of 1 and (phaseollidin), it was found that metabolism the related fungitoxin 5,7,4'-trihydroxy-6- by Fusalium solani f. sp. phaseoli involved a (3,3-dimethylallyl)isoflavone (wighteone) also straightforward hydration of the sidechain to occur on the surface of lupin Ieaves2'3) where, yield kievitone hydrate8) and phaseollidin hy- in conjunction with other isoflavones [e.g. drate,9* respectively.
    [Show full text]